You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 3, March 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Off-Center Fold
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Neoplasms
 •Diagnosis
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Persistent Violaceous Papules on the Ears—Diagnosis

Arch Dermatol. 2007;143(3):417-422.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Diagnosis: Cutaneous diffuse large B-cell lymphoma.

MICROSCOPIC FINDINGS, LABORATORY FINDINGS, AND CLINICAL COURSE

Biopsy specimens revealed a primary cutaneous diffuse large B-cell lymphoma. A dense monomorphous infiltrate of mononuclear cells extended from the upper reticular to the deep dermis. Scattered among the mononuclear cells were larger atypical CD20+ B cells with hyperchromatic nuclei. Immunoperoxidase stains showed a smaller amount of reactive CD45RO+, CD3+, CD5+, and CD79a T cells. Stains were negative for CD30, CD43, and {kappa} and {lambda} immunoglobulin light chains and strongly positive for Bcl-2. Gene rearrangement studies were positive for a monoclonal B-cell population, and polymerase chain reaction analysis revealed an IgG heavy-chain rearrangement. The extent of involvement of the ears made radiation therapy and local excision impractical. Also, considering the expected good prognosis, intensive chemotherapy was inappropriate. The patient was treated with rituximab, a chimeric monoclonal anti-CD20 antibody, at a dosage of 375 mg/m2 per day for 4 consecutive weeks, resulting in complete resolution of her disease.

DISCUSSION

Primary cutaneous . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Persistent Violaceous Papules on the Ears—Quiz Case
Brooke L. Blumetti, Anita C. Gilliam, Kevin D. Cooper, and Stephen E. Helms
Arch Dermatol. 2007;143(3):417-422.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.